Drug Price Trends for BREXAFEMME

Best Wholesale Price for BREXAFEMME

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
BREXAFEMME 150MG	Scynexis, Inc.	75788-0115-04	4	491.24	122.81000	EACH	2023-01-01 - 2027-02-28	FSS
BREXAFEMME 150MG	Scynexis, Inc.	75788-0115-04	4	350.56	87.64000	EACH	2024-01-01 - 2027-02-28	Big4
BREXAFEMME 150MG	Scynexis, Inc.	75788-0115-04	4	535.45	133.86250	EACH	2024-01-01 - 2027-02-28	FSS
BREXAFEMME 150MG	Scynexis, Inc.	75788-0115-04	4	350.58	87.64500	EACH	2022-03-01 - 2027-02-28	Big4
BREXAFEMME 150MG	Scynexis, Inc.	75788-0115-04	4	467.84	116.96000	EACH	2022-03-01 - 2027-02-28	FSS
BREXAFEMME 150MG	Scynexis, Inc.	75788-0115-04	4	357.23	89.30750	EACH	2023-01-01 - 2027-02-28	Big4

Brexafemme: Market Dynamics and Price Projections for Ibrexafungerp

Last updated: February 19, 2026

Brexafemme (ibrexafungerp) is approved for vulvovaginal candidiasis (VVC) and is being investigated for invasive fungal infections. The drug's novel mechanism of action, oral availability, and potential for broad-spectrum activity position it to capture significant market share. Current pricing and projected market penetration indicate substantial revenue potential, contingent on clinical trial outcomes and market adoption.

What is Brexafemme and its Mechanism of Action?

Brexafemme is an orally administered glucan synthase inhibitor. It targets the fungal cell wall, specifically inhibiting the enzyme (1,3)-β-D-glucan synthase. This enzyme is essential for synthesizing β-(1,3)-D-glucan, a primary structural component of the fungal cell wall. Disruption of β-(1,3)-D-glucan synthesis compromises cell wall integrity, leading to osmotic instability and cell lysis.

The drug's chemical structure is a tricyclic carboxamide. It is distinct from azoles and echinocandins, offering a potential solution for drug-resistant fungal strains. Ibrexafungerp is a first-in-class drug that inhibits glucan synthase.

What are the Approved Indications for Brexafemme?

Brexafemme received U.S. Food and Drug Administration (FDA) approval on June 1, 2021, for the treatment of vulvovaginal candidiasis (VVC), both in its complicated and uncomplicated forms.

Key aspects of the VVC indication include:

• Dosage and Administration: A single oral dose of 300 mg of ibrexafungerp twice daily for one day, or a single oral dose of 300 mg once daily for two days [1].
• Target Population: Women aged 12 years and older diagnosed with VVC.
• Efficacy: Clinical trials demonstrated high clinical cure rates compared to placebo and fluconazole in certain VVC patient populations. For instance, in the IVY trial, ibrexafungerp achieved an 89.7% composite cure rate in women with complicated VVC after a single-day, twice-daily regimen [2].

What are the Potential Future Indications Under Investigation?

Beyond VVC, ibrexafungerp is undergoing investigation for several serious and life-threatening invasive fungal infections. These studies aim to expand its therapeutic utility and market reach.

Potential future indications include:

• Invasive Candidiasis: Trials are evaluating ibrexafungerp for treating candidemia and other invasive Candida infections. This is a critical area given the high mortality associated with these infections and the growing threat of azole-resistant Candida species.
• Invasive Aspergillosis: Ibrexafungerp is also being studied for its efficacy against Aspergillus infections, another significant cause of morbidity and mortality in immunocompromised patients.
• Recurrent Vulvovaginal Candidiasis (RVVC): While approved for VVC, ongoing research is exploring its use in preventing recurrent infections.

What is the Current Market Landscape for Antifungal Therapies?

The global antifungal drug market is substantial and growing, driven by increasing incidences of fungal infections, particularly among immunocompromised populations (e.g., cancer patients, organ transplant recipients, HIV/AIDS patients).

Key market segments and players include:

• Azoles: Fluconazole, itraconazole, voriconazole, and posaconazole are widely used but face challenges with resistance and drug-drug interactions. Major manufacturers include Pfizer, Merck, and Gilead Sciences.
• Echinocandins: Caspofungin, micafungin, and anidulafungin are primarily used for invasive candidiasis. These are administered intravenously and are less susceptible to resistance than azoles, but they do not have activity against Aspergillus. Manufacturers include Merck, Astellas Pharma, and Gilead Sciences.
• Polyenes: Amphotericin B is a broad-spectrum agent, but its use is limited by nephrotoxicity.

The market is characterized by a need for oral agents with broad-spectrum activity, favorable safety profiles, and the ability to overcome resistance mechanisms.

How Does Brexafemme Differentiate Itself from Existing Antifungals?

Brexafemme's differentiation stems from its unique class, oral administration, and distinct spectrum of activity.

Key differentiators:

• Novel Mechanism: As a glucan synthase inhibitor, it targets a pathway distinct from azoles (which inhibit ergosterol synthesis) and polyenes (which bind to ergosterol). This allows for potential efficacy against azole-resistant strains.
• Oral Formulation: Offers convenience and potential for outpatient treatment, reducing healthcare costs and patient burden compared to intravenous therapies.
• Broad Spectrum: Demonstrates activity against Candida species, including azole-resistant strains, and is being investigated for Aspergillus.
• Safety Profile: Generally well-tolerated in clinical trials, with common side effects including gastrointestinal disturbances [2].

What is the Current Pricing of Brexafemme?

The pricing of Brexafemme is set to reflect its novel mechanism, oral convenience, and demonstrated efficacy in a significant unmet medical need.

• List Price: The wholesale acquisition cost (WAC) for Brexafemme (ibrexafungerp) for VVC is approximately $700 for a one-day treatment course [3]. This typically involves two 150 mg tablets for a total of 300 mg, taken twice daily for one day, or once daily for two days.

This price positions Brexafemme as a premium treatment option for VVC, comparable to other novel therapies in infectious disease areas.

What are the Projected Market Penetration and Revenue Potential?

The market penetration and revenue potential for Brexafemme are significant, especially with its expansion into broader indications.

VVC Market:

• Market Size: The VVC market in the U.S. is substantial, with millions of cases diagnosed annually.
• Penetration: Brexafemme is expected to capture market share from both over-the-counter (OTC) and prescription azole therapies, particularly in cases of recurrent or complicated VVC.
• Revenue Projection (VVC): Based on its pricing and anticipated market adoption, the VVC indication alone could generate several hundred million dollars annually.

Invasive Fungal Infections Market:

• Market Size: The global market for invasive fungal infections is estimated to be in the billions of dollars, with significant growth driven by immunocompromised patient populations.
• Penetration: If approved for invasive candidiasis and aspergillosis, ibrexafungerp has the potential to become a frontline or second-line therapy, especially against resistant pathogens. Its oral formulation could also enable earlier transition from IV therapy.
• Revenue Projection (Invasive Infections): Success in these indications could lead to blockbuster status, with annual revenues potentially exceeding $1 billion.

Factors influencing penetration and revenue include:

• Clinical Trial Success: Positive outcomes in ongoing trials for invasive fungal infections are critical.
• Payer Reimbursement: Favorable formulary placement and reimbursement policies from insurance providers will be essential.
• Physician Adoption: Education and awareness among healthcare providers regarding its efficacy and safety profile.
• Competition: The emergence of new antifungal agents and evolving resistance patterns.

What are the Key Challenges and Opportunities for Brexafemme?

Brexafemme faces both significant opportunities and challenges that will shape its market trajectory.

Opportunities:

• Unmet Medical Needs: The rise of drug-resistant fungal pathogens creates a strong demand for novel agents like ibrexafungerp.
• Oral Convenience: This is a major advantage over intravenous antifungals, improving patient compliance and reducing healthcare system costs.
• Broad Spectrum Potential: Activity against Candida and Aspergillus broadens its therapeutic utility significantly.
• First-in-Class Status: As a novel class, it offers a new treatment paradigm.

Challenges:

• Physician Education: Educating physicians about a new drug class and its place in therapy requires sustained effort.
• Reimbursement Hurdles: Novel therapies often face initial challenges with formulary access and reimbursement, especially at premium price points.
• Clinical Trial Risk: The success of ongoing clinical trials for invasive fungal infections is not guaranteed.
• Competition: The antifungal market, while evolving, still has established players. New entrants may also emerge.
• Resistance Development: While designed to combat resistance, long-term use could eventually lead to resistance development.

What are the Regulatory Pathways and Timelines?

Brexafemme's regulatory journey has included successful FDA approval for VVC. Future indications will require additional regulatory submissions and approvals.

• VVC Approval: Granted June 1, 2021, by the FDA [1].
• Invasive Fungal Infections: Ongoing Phase 3 trials are expected to provide pivotal data. Submission of New Drug Applications (NDAs) for indications like invasive candidiasis and aspergillosis would follow successful trial completion.
• European Union: Applications for additional indications are likely to be pursued in other major markets following U.S. approvals.

Specific timelines for invasive fungal infection approvals are contingent on trial results and regulatory review processes, typically taking 12-24 months from submission to potential approval.

Key Takeaways

Brexafemme represents a significant advancement in antifungal therapy with a novel mechanism of action and an oral formulation. Its initial approval for VVC positions it for substantial revenue, with projected market penetration influenced by pricing and payer acceptance. The drug’s true market potential hinges on the success of ongoing clinical trials for invasive fungal infections, where it could address critical unmet needs and compete in a multi-billion dollar market. Challenges include physician education and reimbursement, while opportunities lie in its differentiation and broad-spectrum potential.

FAQs

1. What is the difference between Brexafemme and fluconazole? Brexafemme is a glucan synthase inhibitor, while fluconazole is an azole antifungal. Brexafemme targets fungal cell wall synthesis, whereas fluconazole targets ergosterol synthesis. This difference in mechanism means Brexafemme can be effective against some Candida strains that have developed resistance to fluconazole. Brexafemme is also orally administered as a single-day or two-day regimen, offering convenience.

2. How does Brexafemme's pricing compare to other antifungal treatments for VVC? Brexafemme's wholesale acquisition cost of approximately $700 for a VVC treatment course is a premium price compared to many generic oral azoles (e.g., fluconazole), which are available at significantly lower costs. However, it is competitive with other novel oral therapies for infectious diseases and reflects its unique mechanism and convenience.

3. What are the most common side effects of Brexafemme? In clinical trials for VVC, the most common side effects reported were gastrointestinal in nature, including nausea, diarrhea, and abdominal pain. The safety profile for invasive fungal infections is still being established through ongoing studies.

4. What is the significance of ibrexafungerp's broad-spectrum potential? The potential for ibrexafungerp to treat not only Candida infections but also Aspergillus infections is highly significant. Invasive aspergillosis is a life-threatening illness with limited oral treatment options. If successful, this broad spectrum would make ibrexafungerp a versatile and crucial tool in managing serious fungal diseases, particularly in immunocompromised patients.

5. What is the expected timeline for Brexafemme's potential approval for invasive fungal infections? Timelines for regulatory approval of new indications are subject to the successful completion of clinical trials and the subsequent review process by regulatory agencies like the FDA. Pivotal Phase 3 trials are currently underway. Assuming positive data, regulatory submissions could occur in late 2024 or 2025, with potential approvals in 2026 or later, depending on the review duration.

Citations

[1] FDA. (2021, June 1). FDA approves brexafemme (ibrexafungerp) tablets, the first oral glucan synthase inhibitor for the treatment of vulvovaginal candidiasis. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-brexafemme-ibrexafungerp-tablets-first-oral-glucan-synthase-inhibitor-treatment-vulvovaginal

[2] Mycovia Pharmaceuticals. (2022). Brexafemme prescribing information. Retrieved from https://www.brexafemme.com/wp-content/uploads/2022/07/BREXAFEMME_Prescribing_Information.pdf

[3] Drug Pricing & Reimbursement News. (2021, June 2). Candesica’s brexafemme: $700 single-day oral treatment for VVC. Generics and Biosimil News. Retrieved from https://www.genericsandbiosimilaws.com/2021/06/02/candesicas-brexafemme-700-single-day-oral-treatment-for-vvc/